**TLR2 regulates angiotensin II-induced vascular remodeling and EndMT through NF-κB signaling**

Ke Lin¹², Wu Luo¹, Jueqian Yan¹, Siyuan Shen¹², Qirui Shen¹, Jun Wang³, Xinfu Guan⁴, Gaojun Wu², Weijian Huang², Guang Liang¹²⁴

¹Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China  
²Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, Zhejiang, China  
³Department of Cardiology, Wenzhou Central Hospital and Affiliated Dingli Clinical Institute, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China  
⁴Affiliated Cangnan Hospital, Wenzhou Medical University, Cangnan 325800, Zhejiang, China

**Correspondence to:** Guang Liang, Weijian Huang; email: wzmliangguang@163.com, https://orcid.org/0000-0002-8278-849X; weijianhuang69@126.com, https://orcid.org/0000-0003-2958-134X  
**Keywords:** endothelial to mesenchymal transition, TLR2, angiotensin II, vascular remodeling, NF-κB  
**Received:** August 18, 2020  **Accepted:** October 31, 2020  **Published:** December 9, 2020

Copyright: © 2020 Lin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**ABSTRACT**

Excessive vascular remodeling has been shown in hypertensive patients. In experimental models of hypertensive vascular injury, such as angiotensin II (Ang II) challenged mice, toll like receptor 2 (TLR2) initiates inflammatory responses. More recently, studies have reported atypical endothelial to mesenchymal transition (EndMT) in vascular injuries and inflammatory conditions. Here, we aimed to investigate whether TLR2 mediates Ang II-induced vascular inflammation and initiates EndMT. In a mouse model of angiotensin II-induced hypertension, we show that aortas exhibit increased medial thickening, fibrosis, and features of EndMT. These alterations were not observed in TLR2 knockout mice in response to Ang II. TLR2 silencing in cultured endothelial cells confirmed the essential role of TLR2 in Ang II-induced inflammatory factor induction, and EndMT-associated phenotypic change. Mechanistically, we found Ang II activates nuclear factor-κB signaling, inducing pro-inflammatory cytokine production, and mediates EndMT in both cultured endothelial cells and in mice. These studies illustrate a novel role of TLR2 in regulating Ang II-induced deleterious vascular remodeling through the induction of EndMT. The studies also suggest that TLR2 may be targeted to alleviate hypertension-associated vascular injury.

**INTRODUCTION**

Hypertension is an important risk factor of adverse cardiovascular and cerebrovascular events, affecting more than 1 billion people worldwide [1, 2]. Hypertension-associated morphologic and functional changes include alterations in the vasculature and the development of endothelial dysfunction. In response to persistently elevated blood pressure and an imbalance of circulating cytokines, vascular tissues undergo progressive changes of increased extracellular matrix deposition, hyperplasia of smooth muscle cells, and altered vessel resistance [3]. Although the mechanisms are not fully clear, recent studies have shown that angiotensin II (Ang II) is capable of mediating these changes [4, 5]. Studies that elucidate the mechanisms underlying these Ang II activities, whether hemodynamic or nonhemodynamic, are valuable to identify targets for therapy.
Vascular endothelial cells can acquire a mesenchymal phenotype upon irritation or injury, in a process termed endothelial-to-mesenchymal transition (EndMT) [6]. During this cell phenotype switch, endothelial cells undergo a morphological change from a flattened to a fusiform shape, lose their endothelial-selective markers such as CD31 and vascular endothelial-cadherin (VE-cadherin), and begin to express genes associated with mesenchymal cells such as vimentin and α-smooth muscle actin (α-SMA). As this change progresses, cells become increasingly migratory, and contribute to expansive vascular remodeling [7]. EndMT can be induced by a number of factors. One such factor is transforming growth factor-β1 (TGF-β1). Activation of the TGF-β1-Smad signaling pathway induces EndMT transcription factors Snai1 and Snai2 (also known as Slug) that promote EndMT-related changes in cells [8]. It is possible that Ang II also induces EndMT during hypertension-associated vascular remodeling and injury. Xu and colleagues demonstrated that endothelial-specific deletion of Ets-1 attenuates Ang II-induced cardiac fibrosis by suppressing EndMT [9]. In another study, Liu et al showed that a bioactive compound kaempferol suppresses Ang II-induced EndMT in heart tissues and reduces cardiac fibrosis [10].

Although most of the actions of Ang II are attributed to angiotensin II type 1 receptor, recent studies have identified toll like receptors (TLRs) in nonhemodynamic actions of Ang II, especially in the context of disease [11–13]. For example, TLR2 has been shown to regulate Ang II-induced inflammatory responses in heart and kidney tissues [14, 15], and during aortic aneurysms [16] and aortic stenosis [17]. Considering the fact that inflammation is also an inducer of EndMT and endothelial dysfunction [18], we hypothesized that Ang II engages TLR2 to induce EndMT and result in deleterious vascular remodeling. To test this hypothesis, we utilized TLR2 knockout mice and generated vascular dysfunction by exogenous Ang II administration. We show that Ang II activates EndMT-associated changes in aortas of mice, manifesting as induction of EndMT-regulating transcription factors, suppressed levels of endothelial markers, and increased expression of mesenchymal markers. We found that these changes are associated with increased inflammatory responses and matrix protein deposition. TLR2 knockout mice are completely protected against these pathological changes induced by Ang II. We also found that nuclear factor-κB is intricately involved as its inhibition mimics TLR2 deficiency. These results highlight the novel engagement of TLR2 by Ang II to induce EndMT and vascular alterations, and identify TLR2 as a potential therapeutic target.

RESULTS

TLR2 knockout mice are protected against Ang II-induced fibrosis in aortas

In order to investigate the role of TLR2 in Ang II-induced deleterious vascular remodeling, we challenged mice with low-dose Ang II infusion for 2 weeks. We did not observe difference in body weights of mice following Ang II infusion (Figure 1A). TLR2 knockout (TLR2 KO) mice also did not exhibit body weight differences compared to wildtype (WT) mice. Ang II infusion elevated systolic blood pressure in both WT and TLR2 KO mice as expected (Figure 1B). Since chronic inflammation contributes to vascular remodeling [19], and TLR2 regulates inflammatory responses [20], we measured the levels of serum interleukin-6 (IL-6) as a proxy for inflammatory status. Our results show significantly elevated serum IL-6 in WT mice challenged with Ang II (Figure 1C). The level of IL-6 induction was significantly dampened in TLR2 KO mice. Consistent with these findings, TNF-α immunoreactivity was increased in aortas of WT mice upon Ang II exposure but not in aortas from TLR2 KO mice (Figure 1D). We confirmed these findings by measuring mRNA abundance of pro-inflammatory genes and show that TLR2 KO mice are protected against Ang II-induced TNF-α, IL-1β and IL-6 (Figure 1E). This inflammatory readout mimicked expression patterns of fibrosis-associated genes transforming growth factor-β1 (TGF-β1) and collagen type 3 (col-3) (Figure 1F). Importantly, the results show that Ang II causes increased levels of proinflammatory and fibrotic factors in wildtype mice, and that TLR2 knockout mice show significantly dampened responses to Ang II. We then examined aortic tissues of mice and show that Ang II increases medial thickness in WT mice but not TLR2 KO mice (Figure 1G). Trichome staining and collagen 3 immunoreactivity confirmed increased deposition of connective tissue in aortas of wildtype mice (Figure 1H, I). Consistent with other analyses, TLR2 KO mice did not exhibit increased fibrosis in response to Ang II challenge.

Deficiency of TLR2 prevents Ang II-induced EndMT in aortas

Accumulating evidence suggests that EndMT bridges, or at least is associated with, inflammation and vascular injury [18]. To determine whether regulation of EndMT was involved in the protective phenotype of TLR2 KO mice against Ang II, we first performed immunofluorescence labeling of aortic tissues. We stained the sections for endothelial marker CD31 and mesenchymal marker α-SMA. A decrease in CD31 and an increase in α-SMA immunoreactivity was seen in tissues of
Figure 1. TLR2 deficiency prevents Ang II-induced vascular remodeling in mice. Wildtype (WT) and TLR2 knockout (TLR2KO) mice were challenged with Ang II for 2 weeks. Data showing (A) body weights of mice, (B) systolic blood pressure measurements, and (C) levels of...
wildtype mice upon Ang II challenge (Figure 2A). TLR2 KO mice, however, showed significantly less alterations as compared to wildtype mice. Similar to CD31 staining, we also observed levels of vascular endothelial-cadherin (VE-cadherin) to be suppressed by Ang II in WT mice (Figure 2B). No such decreases were noted in TLR2 KO mice challenged with Ang II. Next, we measured mRNA levels of EndMT-associated genes in aortic tissues and found increased levels of Twist1, Snai1, Snai2 (slug) and Vim (vimentin) in WT mice after Ang II exposure (Figure 1C). In addition, Cdh5 (VE-cadherin) mRNA levels were reduced upon Ang II administration. These data suggest an increase in mesenchymal cell transcripts in aortas of mice following Ang II infusion. These mRNA alterations were largely absent in TLR2 KO mice. Collectively, these results indicate that TLR2 may be involved in Ang II-induced EndMT in vascular tissues.

**TLR2 silencing prevents EndMT-associated changes in cultured endothelial cells**

We performed our in vivo studies using whole tissue lysates, which makes it difficult to pinpoint the source of these mRNA and protein alterations. Although we focused on the endothelial lining in our immunofluorescence studies, we need to confirm the role of TLR2 in regulating Ang II-induced EndMT in purified endothelial cell system. To do this, we utilized cultured HUVECs and exposed the cells to Ang II. Initially, we performed an Ang II dose-response and determined how rapidly EndMT-associated proteins are altered. Our results show that 36 h is enough to significantly induce EndMT transcription factors Twist1 and Snail/Slug (Supplementary Figure 1A, 1C). These transcription factors are induced in parallel to increases in mesenchymal markers α-SMA and vimentin, increases in collagen 3, and decreases in endothelial cadherin (Supplementary Figure 1A, 1C). Dose-response studies pointed to 10 µM and higher levels of Ang II mediating EndMT in HUVECs (Supplementary Figure 1B, 1D). Based on these results, we used 10 µM Ang II for subsequent studies. Although higher concentrations of Ang II also induced EndMT in a robust manner, we have elected to use the lowest concentration that elicits a response, in an attempt to avoid saturating and potentially confounding conditions expected from higher concentrations.
Figure 2. TLR2 KO mice are protected against Ang II-induced EndMT in aortas. (A) Representative immunofluorescence staining images showing CD31 (green) and α-SMA (red) in mouse aortic tissues. Arrows indicate positive staining. Tissues were counterstained with DAPI (blue) [scale bar = 30 µm]. Quantification of α-SMA fluorescence in CD31-positive endothelial area is shown on right. (B) Representative immunofluorescence staining images showing CD31 (green) and VE-cadherin (red) in mouse aortic tissues. Arrows indicate positive staining. Tissues were counterstained with DAPI (blue) [scale bar = 30 µm]. Quantification of VE-cadherin in CD31-positive endothelial area is shown on right. (C) mRNA levels of EndMT-associated genes in aortas [Data normalized to β-actin]. [n = 6-8; Data shown as Mean ± SEM; *p<0.05, **p<0.01, and ***p<0.001 compared to WT; #p<0.05 and ##p<0.01 compared to WT-Ang II].
Figure 3. Silencing TLR2 prevents EndMT phenotype in cultured endothelial cells. (A) HUVECs were transfected with siRNA against TLR2. Control cells were transfected with negative control (NC) siRNA. Cells were then challenged with 10 μM Ang II for 36 h. Total proteins were probed for TLR2 and EndMT-associated proteins. GAPDH was used as loading control. (B, C) HUVECs were exposed to 10 μM Ang II for 24 h, after siRNA transfections. mRNA levels of EndMT-associated genes were determined. Data was normalized to β-actin. (D) Representative immunofluorescence staining of HUVECs for CD31 (green) and α-SMA (red). Cells were transfected with indicated siRNA and then exposed to 10 μM Ang II for 36 h. Slides were counterstained with DAPI (blue). Arrows indicate HUVECs undergoing EndMT, as evident through loss of CD31 and induction of α-SMA [Scale bar = 50 μm]. n = 3; Data shown as Mean ± SEM; *p<0.05 and **p<0.01, compared to negative control transfection; #p<0.05 and ##p<0.01 compared to Ang II challenged negative control transfection].
Figure 4. TLR2 regulates EndMT through NF-κB. (A) HUVECs were pretreated with NF-κB inhibitor Bay 11-7085 at 5 μM for 1 h. Cells were then exposed to 10 μM Ang II for 36 h. Levels of EndMT proteins were detected by immunoblotting. GAPDH was used as loading control. (B) HUVECs were transfected with TLR2 siRNA or negative control siRNA. Transfected cells were exposed to 10 μM Ang II for 2 h. Total proteins, and nuclear and cytoplasmic fractions were probed for NF-κB p65 subunit and inhibitor of κBα (IκB). GAPDH was used as loading control for total proteins and cytosolic fractions. Lamin B was used as loading control for nuclear fractions. (C) Cells treated as indicated in Panel B were stained for p65 subunit (red). Counterstaining with DAPI was performed [scale bar = 25 μm]. (D) Quantitative analysis of nuclear p65 staining in HUVECs. Representative staining images are shown in panel C. (E) HUVECs expressing NFκB-EGFP reporter were transfected with NC siRNA or TLR2 siRNA, and challenged with 10 μM Ang II for 2 h. Representative images of EGFP (green) fluorescence of each group are shown [scale bar = 100 μm]. (F) Immunofluorescence staining of aortic tissues for CD31 (green) and NF-κB p65 (red). Tissues were counterstained with DAPI [scale bar = 30 μm]. Inserts showing high-power images of tissues (arrows indicating endothelial cells). (G) Quantitative fluorescence intensity of p65 in tissues, expressed as percent positive cells. Representative fluorescence images are shown in panel F. [n = 3 in A-E; n = 7 per group in F and G; Data shown as Mean ± SEM; ***p<0.001 compared to negative control siRNA transfection (D) or wildtype mice (G); #p<0.05 compared to NC siRNA+Ang II (D) or WT-Ang II (G)].
EGFP reporter for NF-κB transcriptional activity, we obtained similar results in NF-κB-EGFP-transfected HUVECs with scrambled siRNA or TLR2 siRNA (Figure 4E, Supplementary Figure 5E). Specifically, TLR2 silencing reduced Ang II-induced NF-κB activity. We also examined the levels of NF-κB p65 in aortic tissues of WT and TLR2 KO mice to confirm the involvement of NF-κB in this signaling axis. As expected, Ang II significantly increased aortic NF-κB p65 levels in WT mice, with a significantly suppressed response in TLR2 KO mice (Figure 4F, 4G).

**Ang II causes endothelial cells to release paracrine factors which mediate EndMT in a TLR2-independent mechanism**

Our next objective was to determine whether Ang II-TLR2-NF-κB axis is involved in the elaboration of inflammatory factors. Exposure of HUVECs to Ang II showed higher levels of Tnfa, Il6, and Il1b mRNA levels (Figure 5A–5C). These inductions were prevented in HUVECs transfected with TLR2 siRNA. Based on these data, we explored the possibility that Ang II-induced inflammatory and other paracrine factors may contribute to EndMT, in a pathway that may also depend on TLR2. To test this, we exposed HUVECs to Ang II and collected the condition media. This condition media, which comprised Ang II-induced inflammatory cytokines, was applied to a separate set of cells transfected with scrambled or TLR2 targeting siRNA (Figure 5D). When condition media from Ang II-challenged cells was applied to control HUVECs, EndMT switch was evident (Figure 5E, Supplementary Figure 6). However, TLR2 deficiency was not able to offer protection against Ang II condition media, indicating that inflammatory and other paracrine factors released from cells activate EndMT through a TLR2-independent mechanism. Taken together, our results suggest that TLR2 signaling regulates Ang II-induced NF-κB activation and inflammatory cytokine release, and subsequently mediates EndMT. However, TLR2 may not be able to circumvent EndMT switch triggered by inflammatory factors and other mechanisms.

**DISCUSSION**

In our study, we have shown that deficiency of TLR2 suppresses the activation of NF-κB in response to Ang II administration. This signaling pathway is critically involved in the secretion of inflammatory cytokines, deposition of matrix proteins, and initiation of EndMT. Deficiency in TLR2 largely prevents the development of these pathogenic changes in aortas. A schematic illustrating the main findings is shown in Figure 6.

Elevated Ang II has been linked to heart damage and kidney injury, as well as to vascular injuries [22–24]. Recent evidence has also shown that TLR2 regulates Ang II-induced cellular and tissue damage [14, 15, 24, 25]. TLR2 deficiency or inhibition is able to improve Ang II-induced cardiac damage, in part by suppressing the infiltration of macrophages [15]. Yan and colleagues also found that blocking TLR2 signaling decreases Ang II-induced chronic inflammation and vascular remodeling in models of abdominal aortic aneurysm [25]. Furthermore, miR-144-5p was found to regulate TLR2 signaling and the progression of aortic aneurysms following Ang II administration in apolipoprotein E knockout mice [24]. These studies suggest that some of the adverse effects of Ang II in vascular tissues may be regulated by TLR2. In agreement with this role, we show that mice deficient in TLR2 do not exhibit aortic lesions that are seen by chronic Ang II administration.

One mechanism that we have not been able to elucidate is how Ang II engages TLR2. It is unknown whether there is a direct interaction between Ang II and TLR2 or indirect activation by elaboration of TLR2 ligands, which may be generated through Ang II signaling. Based on our current understanding, it is possible that both hemodynamic and nonhemodynamic actions of Ang II are involved in TLR2 activation and vascular remodeling. For example, increased shear stress may be involved [26]. Inflammatory responses and increased oxidative stress may also contribute to vascular remodeling, independent of the regulation of blood pressure [22]. In support of this mechanism, Steven and colleagues showed that caveolin-1 deletion prevents vascular inflammation and remodeling, independent of systolic blood pressure changes in mice [27]. Ang II may potentially increase oxidative stress through Ang II receptors in vascular cells [28, 29]. In our study, we report that TLR2 knockout mice do not show any alteration in Ang II-induced systolic blood pressure, which was comparable to wildtype mice and consistent with previous reports [15]. It remains to be determined whether preventing inflammatory responses, increased oxidative stress, or Ang II receptors is able to prevent TLR2 activation.

The developmental EndMT process is gaining traction as being intimately involved in various forms of vascular injury [18, 30, 31]. Cardiovascular conditions such as cardiac fibrosis and atherosclerosis show induction of EndMT [32]. Furthermore, Ang II has been found to induce EndMT, in part through TGF-β signaling [33]. Inflammatory factors may also mediate Ang II-induced EndMT [34]. We empirically showed the association of TGF-β1, TGF-β1 signaling proteins Smad2/3, as well as induction of inflammatory cytokines by Ang II in endothelial cells and in aortas of
mice. Removing TLR2 from the equation prevents the alteration of these various signaling axes. Furthermore, the downstream manifestation of these signaling aberrations, EndMT, is prevented when TLR2 is not present. It would be interesting to examine whether blocking signaling pathways singularly, for example inflammatory factors alone or TGF-β1 alone, would alter Ang II-induced EndMT or whether this complex cellular phenotype switch requires convergence of all activating axes. At least one aspect is clear in our study: the requirement of NF-κB to bring about these changes. NF-κB may be activated by TGF-β1, oxidative stress, inflammatory factors, Ang II receptor signaling, as well as by TLRs. Every pathway we have examined is easily linked to NF-κB. Other researchers have also shown that NF-κB activation increases the levels of α-SMA [35]. Li et al. demonstrated that activation of NF-κB regulates EndMT in type I diabetes [36]. Furthermore, Maleszewska et al. showed that TGF-β2 and IL-1β induce EndMT in a NF-κB-dependent manner [37]. Our study can be added to this list in implicating NF-κB as a central hub for EndMT initiation.

Increased inflammatory cytokines and other paracrine factors released in response to Ang II may also cause EndMT. Early studies conducted by Montesano and colleagues in the 1980s showed that condition medium from activated lymphocytes induces a fibroblast-like morphology in HUVECs [38]. Exposure of endothelial cells to TNF-α and IL-1β also induces EndMT [39, 40]. Moreover, Sánchez et al. found that exposure of endothelial cells to TNF-α or IL-1β individually is

Figure 5. Blockade of TLR2 signaling does not affect downstream processes of inflammatory factors and EndMT. (A–C) HUVECs were transfected TLR2 or negative control siRNA. Cells were then exposed to 10 μM Ang II for 6h. mRNA levels of proinflammatory factors were detected [data normalized to β-actin]. (D) Schematic illustration of the experimental model to test the role of Ang II-induced paracrine factors in EndMT. Conditioned media was collected from cells challenged with 10 μM Ang II for 24 h. Media was then added to HUVECs transfected with TLR2 or negative control siRNA. (E) Levels of TLR2 and EndMT-associated proteins were determined in cells treated in panel D. GAPDH was used as loading control. [n = 3; Data shown as Mean ± SEM; **p<0.01 compared to negative control; #p<0.05 and ##p<0.01 compared to Ang II exposed negative control].
sufficient to change the cell phenotype in human primary aortic endothelial cells [30]. Although we noted increased mRNA levels of \textit{Tnfa}, \textit{Il6}, and \textit{Il1b}, we did not test whether neutralizing these factors would reduce Ang II-induced EndMT. Furthermore, our studies indicate that TLR2 deficiency is unable to prevent EndMT induced by condition media from cells that had been challenged with Ang II. The likely explanation is that TLR2 deficiency fails to inhibit NF-\kappaB, which is activated by inflammatory and other paracrine factors in the condition media. Other possibilities include autophagy [41], and activation of protein kinase B (Akt) and mitogen-activated protein kinase pathways [42], which may be at play. A comprehensive understanding of these inducers will greatly aid the identification of interventional and effective therapies.

A limitation of our studies that needs a mention is that we are unable to examine mRNA and proteins exclusively from endothelial cells in aortic tissues. Our \textit{in vivo} studies utilized whole tissue lysates that would comprise vascular smooth muscle cells and infiltrating inflammatory cells. Therefore, based on \textit{in vivo} studies alone, we are unable to conclude that Ang II induces inflammatory factors in endothelial cells. To circumvent this limitation, we carried out immunofluorescence staining of tissues to focus on the endothelial lining of aortas. In addition, we utilized the purified endothelial culture system to offer such insights. In particular, we show that Ang II induces EndMT in purified endothelial cells and that TLR2 knockdown negates these changes. We also should that Ang II induces inflammatory factors in cultured endothelial cells. When considered together with the \textit{in vivo} studies, our hypothesis appears to hold true. Future studies utilizing endothelial-specific TLR2 knockout would be extremely beneficial in advancing this field.

Figure 6. Schematic illustration of the main findings. Ang II potentially engages TLR2 signaling pathway to activate NF-\kappaB in vascular endothelial cells. NF-\kappaB orchestrates the induction of EndMT transcription factors to reduce endothelial phenotype makeup and increase mesenchymal genes. In addition to regulating cell phenotype change, NF-\kappaB increases the expression of extracellular matrix proteins. Ang II may cause the production and release of paracrine factors which may further facilitate EndMT in a TLR2-independent manner. Dotted lines indicate putative mechanisms where direct evidence of the underlying phenomenon is needed. These putative mechanisms include evidence that Ang II directly engages TLR2 and receptors or sensors involved in detecting and responding to Ang II-generated paracrine factors.
In summary, we found that Ang II causes EndMT in aortas of mice and cultured cells through activating TLR2. We also report that NF-κB may mediate most of the pathological changes seen such as increased extracellular matrix deposition and elaboration of inflammatory cytokines. Deficiency in TLR2 downregulates the activation of NF-κB, thereby relieving the injury, possibly through suppression of EndMT. These studies suggest that TLR2 and NF-κB may be promising in preventing hypertension-associated vascular diseases.

**MATERIALS AND METHODS**

**Reagents**

Human umbilical vein endothelial cells (HUVECs) were obtained from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). HUVECs were cultured in Dulbecco’s modified Eagle 110 medium with 10% fetal bovine serum, 100 U/mL penicillin and 100 U/mL streptomycin at 37°C in a humidified 5% CO2 incubator.

Ang II (>90% purity) was purchased from Aladdin (Shanghai China). NF-κB inhibitor (E)-3-(4-t-Butylphenylsulfonyl)-2-propanenitrile (Bay 11-7085; B5681) was obtained from Sigma (St. Louis, MO, USA). Antibodies against inhibitor of κB-α (IκB; 4812S), NF-κB p65 (8242S), TLR2 (12276) and GADPH (5174) were purchased from Cell Signaling Technology (Boston, USA). Antibodies against phosphorylated-Smad2/3 (p-Smad2/3; sc-11769) were obtained from Santa Cruz Biotechnology (CA, USA). Lamin B (ab133741), tumor necrosis factor-α (TNF-α; ab6671), transforming growth factor-β1 (TGF-β1; ab92486), Col-3 (ab7778), Vimentin (ab8978), Snail/Slug (ab180714), smooth muscle actin (α-SMA; ab5694), vascular endothelial cadherin (VE-cadherin; ab9104), Twist (ab50581) and CD31 (ab28364, ab6543) were obtained from Abcam (Cambridge, UK). Secondary antibodies were obtained from Yeasen Biotech (Shanghai, China).

Ang II-induced vascular remodeling in mice

All animal care and experimental procedures were approved by the Wenzhou Medical University Animal Policy and Welfare Committee (Approval Document No. wydw2016-0124). All animals received humane care according to the National Institutes of Health (USA) guidelines. Studies followed the ARRIVE guidelines for reporting experiments involving animals [43].

C57BL/6 male mice were obtained from Animal Center of Wenzhou Medical University. Male TLR2 knockout (TLR2 KO; B6.129-TLR2tm1Kir/J) on C57BL/6 background were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Eight-week-old mice (15 C57BL/6 mice and 13 TLR2KO mice) were housed with a 12:12 h light–dark cycle at a constant room temperature and fed a standard rodent diet. The animals were acclimatized to the laboratory for at least 2 weeks before initiating the studies.

WT and TLR2 KO mice were divided into 2 groups each: untreated C57BL/6 mice (WT, n = 8), untreated TLR2 KO mice (n = 6), WT mice treated with Ang II (n = 7), and TLR2 KO mice treated with Ang II (n = 7). Ang II was administered using a micro-osmotic pump (1002, Alzet, USA) as previously reported [44]. The pump was implanted subcutaneously in the back of mice and delivered 1000 ng/kg/min Ang II for 2 weeks. Systolic blood pressure was measured weekly by tail-cuff using the telemetric blood pressure system (BP-2010A, Softron Biotechnology, Tokyo, Japan), as described previously [15]. Measurements were performed during daytime (1:00 pm to 5:00 pm) with previous 5 days of training. At the conclusion of the study, mice were sacrificed, and aortas were excised. Serum levels of interleukin-6 (IL-6) were detected by ELISA (85-88-7064-76; Thermo Fisher).

**Histology and tissue staining**

Tissues were embedded in optical cutting temperature compound (Sakura, Japan). Five micron-thick sections were stained with hematoxylin and eosin (H&E) to assess intimal thickening. Sections were also stained with Masson’s Trichrome staining to examine fibrosis. For immunohistochemical staining, tissue sections fixed. Endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide. Slides were blocked in 5% bovine serum albumin for 30 min. Primary antibodies (collagen III, 1:500; TNF-α, 1:500) were then applied at 4°C overnight. Horseradish peroxidase-conjugated secondary antibodies and diaminobenzidine (DAB) was used for detecting immunoreactivity. Slides were counterstained with hematoxylin.

For immunofluorescence staining, 5-μm tissue sections were used. Cells cultured on gelatin-coated glass slides were also stained. Slides were permeabilized with 0.1% Triton X-100 for 10 minutes and blocked with 5% bovine serum albumin for 45 minutes. Primary antibodies were applied at 4°C overnight. These antibodies included CD31 (1:200), vimentin (1:200), α-SMA (1:200), VE-Cadherin (1:200), and NF-κB p65 (1:200). Alexa Fluor-488, Alexa Fluor-TRITC, and Alexa Fluor-647 were used for detection. Slides were counterstained with DAPI for 5 min. For double labeling, antibodies (primary and secondary) were
applied sequentially. Fluorescence images were acquired using Leica TCS SP8 confocal laser scanning microscope (Buffalo Grove, USA). Nikon microscope (Nikon, Japan) was used for brightfield images.

**TLR2 silencing**

TLR2 was silenced in HUVECs by siRNA transfection. TLR2 siRNA sequences were purchased from Gene Pharma Co. LTD. (Shanghai, China). Sequence is provided in Supplementary Table 1. Control transfections were performed with scrambled siRNA sequences (Gene Pharma). siRNAs were transfected using LipofectAMINE 2000 (Thermo Fisher, Carlsbad, CA).

**Generation of NF-κB EGFP expressing cells**

Stable NF-κB reporter transfections were performed in HUVECs using pGL3-NF-κB-EGFP lentiviral particles. Lentivirus containing the response element (RE) of NF-κB was first obtained by transfecting HEK-293T cells with p-LV-NFκB-RE-EGFP (Thermo Fisher) using Polyethyleneimine (Sigma). Supernatant was collected 48 h later and passed through a 0.45 μm filter. Then, HUVECs were incubated with the supernatant and 8 μg/mL polybrene (Sigma-Aldrich) for 12 h. To select for transfected cells, 1 μg/mL puromycin (Thermo Fisher) was added to the culture media. Following purification of NF-κB reporter expressing cells, cells were transfected with scrambled siRNA or TLR2 siRNA. Cells were then exposed to 10 μM Ang II for 2 h. The EGFP signal was determined from fluorescence images.

**Real-time quantitative PCR**

Total RNA was isolated from cultured cells and aortic vessels using TRIZOL (Thermo Fisher). Reverse transcription and quantitative PCR was carried out using two-step PrimeScript RT reagent Kit (Perfect Real Time; TAKARA) and Eppendorf Mastercycler ep realplex detection system (Eppendorf, Hamburg, Germany). Primers for genes were synthesized and obtained from Thermo Fisher. Sequences are presented in Supplementary Table 1. mRNA of target genes was normalized to β-actin housekeeping gene.

**Western blot analysis**

Sixty micrograms of cell and tissue lysates were separated by 10% SDS-PAGE and electro-transferred to a PVDF membranes. Membranes were blocked in Tris-buffered saline containing 0.05% Tween20 and 5% non-fat milk for 1.5 h. PVDF membranes were then incubated with specific primary antibodies. Immunoreactive bands were detected by incubating with secondary antibodies conjugated to horseradish peroxidase and enhanced chemi-luminescence reagent (Bio-Rad). For some studies, cytosolic and nuclear fractions were separated by using nuclear protein extraction kit (Beyotime Biotech). For these studies, a total of 20 μg nuclear proteins and 40 μg cytosolic proteins were used for immunoblotting. Densitometric quantification was performed using Image J analysis software version 1.38e and normalized to their respective control (GAPDH for cytosolic proteins and Lamin B for nuclear fractions).

**Statistical analysis**

Data shown is from 3 independent experiments, each with 3 replicates for cell studies and 6-8 replicates for mouse studies. Data is expressed as Mean ± SEM. Statistical analysis was performed with GraphPad Prism 8.0 software (San Diego, CA, USA). We used one-way ANOVA followed by Dunnett's post hoc test when comparing more than two groups of data. P values of < 0.05 were considered statistically significant. Post-tests were run if F achieved p < 0.05 and there was no significant variance in homogeneity.

**Abbreviations**

Acta2: α-SMA, α-smooth muscle actin; Ang II: Angiotensin II; BAY: Bay 117805; nuclear factor-κB inhibitor; CD31: cluster of differentiation 31; endothelial marker; Col-3: collagen type 3; DAB: diaminobenzidine; DAPI: 4′:6-diamidino-2-phenylindole; EGFP: enhanced green fluorescent protein; EndMT: endothelial to mesenchymal transition; GAPDH: glyceraldehyde-phosphate dehydrogenase; H&E: hematoxylin and eosin; HUVECs: Human umbilical vein endothelial cells; IL-1β: interleukin 1β; IL-6: interleukin 6; IkB-α: inhibitor of κBα; KO: knockout; NF-κB: nuclear factor kappa-B; PBS: phosphate-buffered saline; qPCR: quantitative polymerase chain reaction; SDS: sodium dodecyl sulfate; TLR2: Toll-like receptor 2; TGF-β1: transforming growth factor-β1; TNF-α: tumor necrosis factor-α; VE-Cadherin: vascular endothelial-cadherin; α-SMA: α smooth muscle actin.

**AUTHOR CONTRIBUTIONS**

This work was carried out in collaboration among all authors. G.L., W.H., and G.W contributed to the literature search and study design. G.L. and G.W. participated in the drafting of the article. K.L., W.L., J.Y., S.S., Q.S., and J.W. carried out the experiments. K.L. and X.G. revised the manuscript. J.W. and G.W. contributed to data collection and analysis. All authors have read and approved the final manuscript.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest.

FUNDING
This study was supported by the National Key Research Project (2017YFA0506000 to G.L.), National Natural Science Foundation of China (81770799 to X.G., 21961142009 to G.L.), Natural Science Foundation of Zhejiang Province (LY18H020013 to J.W. and LY19H020004 to G.W.), Zhejiang Provincial Key Scientific Project (2018C03068 to G.L.), and Wenzhou Science and Technology Key Project (2018ZY009 to G.L.).

REFERENCES

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018; 392:1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7 PMID: 30496104

2. WHO. A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis. WHO Press: Geneva. 2013:pp.1–40.

3. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol. 2004; 287:H435–46. https://doi.org/10.1152/ajpheart.00262.2004 PMID: 15277186

4. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000; 52:11–34. PMID: 10699153

5. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Böhm M, Meinertz T, Münzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999; 99:2027–33. https://doi.org/10.1161/01.cir.99.15.2027 PMID: 10209008

6. Chen PY, Qin L, Baeyens N, Li G, Afolabi T, Budatha M, Tellides G, Schwartz MA, Simons M. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest. 2015; 125:4514–28. https://doi.org/10.1172/JCI82719 PMID: 26517696

7. von Gise A, Pu WT. Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ Res. 2012; 110:1628–45. https://doi.org/10.1161/CIRCRESAHA.111.259960 PMID: 22679138

8. Pardali E, Sanchez-Duffhues G, Gomez-Puerto MC, Ten Dijke P. TGF-β-induced endothelial-mesenchymal transition in fibrotic diseases. Int J Mol Sci. 2017; 18:2157. https://doi.org/10.3390/ijms18102157 PMID: 29039786

9. Xu L, Fu M, Chen D, Han W, Ostrowski MC, Grossfeld P, Gao P, Ye M. Endothelial-specific deletion of Ets-1 attenuates angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition. BMB Rep. 2019; 52:595–600. https://doi.org/10.5483/BMBRep.2019.52.10.206 PMID: 30670148

10. Liu Y, Gao L, Guo S, Liu Y, Zhao X, Li R, Yan X, Li Y, Wang S, Niu X, Yao L, Zhang Y, Li L, Yang H. Kaempferol alleviates angiotensin II-induced cardiac dysfunction and interstitial fibrosis in mice. Cell Physiol Biochem. 2017; 43:2253–63. https://doi.org/10.1159/000484304 PMID: 29073623

11. Fukuda D, Nishimoto S, Aini K, Tanaka A, Nishiguchi T, Kim-Kaneyama JR, Lei XF, Masuda K, Naruto T, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, et al. Toll-like receptor 9 plays a pivotal role in angiotensin II-induced atherosclerosis. J Am Heart Assoc. 2019; 8:e010860. https://doi.org/10.1161/JAHA.118.010860 PMID: 30905257

12. Nunes KP, Bomfim GF, Toque HA, Szasz T, Clinton Webb R. Toll-like receptor 4 (TLR4) impairs nitric oxide contributing to angiotensin II-induced cavernosal dysfunction. Life Sci. 2017; 191:219–26. https://doi.org/10.1016/j.lfs.2017.10.014 PMID: 29032115

13. Pushpakumar S, Ren L, Kundu S, Gamon A, Tyagi SC, Sen U. Toll-like receptor 4 deficiency reduces oxidative stress and macrophage mediated inflammation in hypertensive kidney. Sci Rep. 2017; 7:6349. https://doi.org/10.1038/s41598-017-06484-6 PMID: 28743964

14. Chung S, Jeong JY, Chang YK, Choi DE, Na KR, Lim BJ, Lee KW. Concomitant inhibition of renin angiotensin system and toll-like receptor 2 attenuates renal injury in unilateral ureteral obstructed mice. Korean J Intern Med. 2016; 31:323–34. https://doi.org/10.3904/kjim.2015.004 PMID: 26932402
15. Wang L, Li YL, Zhang CC, Cui W, Wang X, Xia Y, Du J, Li HH. Inhibition of toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. Cardiovasc Res. 2014; 101:383–92. https://doi.org/10.1093/cvr/cvt258 PMID:24259498

16. Owens AP 3rd, Rateri DL, Howatt DA, Moore KJ, Tobias PS, Curtiss LK, Lu H, Cassis LA, Daugherty A. MyD88 deficiency attenuates angiotensin II-induced abdominal aortic aneurysm formation independent of signaling through toll-like receptors 2 and 4. Arterioscler Thromb Vasc Biol. 2011; 31:2813–19. https://doi.org/10.1161/ATVBAHA.111.238642 PMID:21960563

17. Rabkin SW, Lodhia P, Luong MW. P38 MAP kinase in valve interstitial cells is activated by angiotensin II or nitric oxide/peroxynitrite, but reduced by toll-like receptor-2 stimulation. J Heart Valve Dis. 2009; 18:653–61. PMID:20099714

18. Cho JG, Lee A, Chang W, Lee MS, Kim J. Endothelial to mesenchymal transition represents a key link in the interaction between inflammation and endothelial dysfunction. Front Immunol. 2018; 9:294. https://doi.org/10.3389/fimmu.2018.00294 PMID:29515588

19. Whiteford JR, De Rossi G, Woodfin A. Mutually Supportive Mechanisms of Inflammation and Vascular Remodeling. Int Rev Cell Mol Biol. 2016; 326:201–78. https://doi.org/10.1016/bs.ircmb.2016.05.001 PMID:27572130

20. Lalancette-Hébert M, Faustino J, Thammisetty SS, Chip S, Vexler ZS, Kriz J. Live imaging of the innate immune response in neonates reveals differential TLR2 dependent activation patterns in sterile inflammation and infection. Brain Behav Immun. 2017; 65:312–27. https://doi.org/10.1016/j.bbi.2017.05.020 PMID:28579520

21. Ambrozova G, Fidlerova T, Verescakova H, Koudelka A, Rudolph TK, Woodcock SR, Freeman BA, Kubala L, Pekarova M. Nitro-oleic acid inhibits vascular endothelial inflammatory responses and the endothelial-mesenchymal transition. Biochim Biophys Acta. 2016; 1860:2428–37. https://doi.org/10.1016/j.bbagen.2016.07.010 PMID:27431604

22. Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep. 2014; 16:431. https://doi.org/10.1007/s11906-014-0431-2 PMID:24760441

23. Nishiyama A, Kobori H. Independent regulation of renin-angiotensin-aldosterone system in the kidney. Clin Exp Nephrol. 2018; 22:1231–39. https://doi.org/10.1007/s10157-018-1567-1 PMID:29600408

24. Shi X, Ma W, Li Y, Wang H, Pan S, Tian Y, Xu C, Li L. MiR-144-5p limits experimental abdominal aortic aneurysm formation by mitigating M1 macrophage-associated inflammation: suppression of TLR2 and OLR1. J Mol Cell Cardiol. 2020; 143:1–14. https://doi.org/10.1016/j.yjmcc.2020.04.008 PMID:32278833

25. Yan H, Cui B, Zhang X, Fu X, Yan J, Wang X, Lv X, Chen Z, Hu Z. Antagonism of toll-like receptor 2 attenuates the formation and progression of abdominal aortic aneurysm. Acta Pharm Sin B. 2015; 5:176–87. https://doi.org/10.1016/j.apsb.2015.03.007 PMID:26579444

26. Baeyens N, Bandyopadhyay C, Coon BG, Yun S, Schwartz MA. Endothelial fluid shear stress sensing in vascular health and disease. J Clin Invest. 2016; 126:821–28. https://doi.org/10.1172/JCI83083 PMID:26928035

27. Forrester SJ, Elliott KJ, Kawai T, Obama T, Boyer MJ, Preston KJ, Yan Z, Eguchi S, Rizzo V. Caveolin-1 deletion prevents hypertensive vascular remodeling induced by angiotensin II. Hypertension. 2017; 69:79–86. https://doi.org/10.1161/HYPERTENSIONAHA.116.08278

28. Viel EC, Lemarié CA, Benkirane K, Paradis P, Schiffrin EL. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol. 2010; 298:H938–44. https://doi.org/10.1152/ajpheart.00707.2009 PMID:20044442

29. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension. 2004; 44:264–70. https://doi.org/10.1161/01.HYP.0000138688.78906.6b PMID:15262905

30. Sánchez-Duffhues G, García de Vinuesa A, van de Pol V, Geerts ME, de Vries MR, Janson SG, van Dam H, Lindeman JH, Goumans MJ, Ten Dijke P. Inflammation induces endothelial-to-mesenchymal transition and promotes vascular calcification through downregulation of BMPR2. J Pathol. 2019; 247:333–46. https://doi.org/10.1002/path.5193 PMID:30430573

31. Bischoff J. Endothelial-to-mesenchymal transition. Circ Res. 2019; 124:1163–65.
32. Kovacic JC, Dimmel S, Harvey RP, Finkel T, Aikawa E, Krenning G, Baker AH. Endothelial to mesenchymal transition in cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019; 73:190–209. https://doi.org/10.1016/j.jacc.2018.09.089 PMID:30654892

33. Tang RN, Lv LL, Zhang JD, Dai HY, Li Q, Zheng M, Ni J, Ma KL, Liu BC. Effects of angiotensin II receptor blocker on myocardial endothelial-to-mesenchymal transition in diabetic rats. Int J Cardiol. 2013; 162:92–99. https://doi.org/10.1016/j.ijcard.2011.06.052 PMID:21704391

34. You S, Qian J, Wu G, Qian Y, Wang Z, Chen T, Wang J, Huang W, Liang G. Schizandrins B attenuates angiotensin II induced endothelial to mesenchymal transition in vascular endothelium by suppressing NF-kB activation. Phytomedicine. 2019; 62:152955. https://doi.org/10.1016/j.phymed.2019.152955 PMID:31146168

35. Arciniegas E, Carrillo LM, De Sanctis JB, Candelle D. Possible role of NFkappaB in the embryonic vascular remodeling and the endothelial mesenchymal transition process. Cell Adh Migr. 2008; 2:17–29. https://doi.org/10.4161/cam.2.1.5789 PMID:19262121

36. Li Q, Yao Y, Shi S, Zhou M, Zhou Y, Wang M, Chiu JJ, Huang Z, Zhang W, Liu M, Wang Q, Tu X. Inhibition of miR-21 alleviated cardiac perivasal fibrosis via repressing EndMT in T1DM. J Cell Mol Med. 2020; 24:910–20. https://doi.org/10.1111/jcmm.14800 PMID:31680453

37. Maleszewiska M, Moonen JR, Huikjman N, van de Sluis B, Krenning G, Harmsen MC. IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner. Immunobiology. 2013; 218:443–54. https://doi.org/10.1016/j.imbio.2012.05.026 PMID:22739237

38. Montesano R, Mossaz A, Ryser JE, Orci L, Vassalli P. Leukocyte interleukins induce cultured endothelial cells to produce a highly organized, glycosaminoglycan-rich pericellular matrix. J Cell Biol. 1984; 99:1706–15. https://doi.org/10.1083/jcb.99.5.1706 PMID:6333426

39. Liguori TT, Liguori GR, Moreira LF, Harmsen MC. Adipose tissue-derived stromal cells’ conditioned medium modulates endothelial-mesenchymal transition induced by IL-1β/TGF-β2 but does not restore endothelial function. Cell Prolif. 2019; 52:e12629. https://doi.org/10.1111/cpr.12629 PMID:31468648

40. Yoshimatsu Y, Wakabayashi I, Kimuro S, Takahashi N, Takahashi K, Kobayashi M, Maishi N, Podyema-Inoue KA, Hida K, Miyazono K, Watabe T. TNF-α enhances TGF-β-induced endothelial-to-mesenchymal transition via TGF-β signal augmentation. Cancer Sci. 2020; 111:2385–99. https://doi.org/10.1111/cas.14455 PMID:32385953

41. Takagaki Y, Lee SM, Dongqing Z, Kitada M, Kasasaki K, Koya D. Endothelial autophagy deficiency induces IL6-dependent endothelial mesenchymal transition and organ fibrosis. Autophagy. 2020; 16:1905–14. https://doi.org/10.1080/15548627.2020.1713641 PMID:31965901

42. Mahler GJ, Farrar EJ, Butcher JT. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler Thromb Vasc Biol. 2013; 33:121–30. https://doi.org/10.1161/ATVBAHA.112.300504 PMID:23104848

43. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol. 2010; 160:1573–76. https://doi.org/10.1111/j.1476-5381.2010.00873.x PMID:20649560

44. Ye S, Luo W, Khan ZA, Wu G, Xuan L, Shan P, Lin K, Chen T, Wang J, Hu X, Wang S, Huang W, Liang G. Celastrol attenuates angiotensin II-induced cardiac remodeling by targeting STAT3. Circ Res. 2020; 126:1007–23. https://doi.org/10.1161/CIRCRESAHA.119.315861 PMID:32098592
Supplementary Figure 1. Ang II induces EndMT in cultured endothelial cells. (A) HUVECs were exposed to 10 µM Ang II for various time points. PBS was used as vehicle control. Cell lysates were subjected to immunoblotting to assess EndMT. Levels of endothelial marker VE-cadherin, mesenchymal markers α-SMA and Vimentin, EndMT-associated transcription factors Snail/Slug and Twist, and extracellular protein Collagen-3 were detected. GAPDH was used as loading control. (B) HUVECs were exposed to varying concentrations of Ang II for 36 h. Lysates were used for western blot as described in panel A. (C) Densitometric quantification of blots shown in panel A. (D) Densitometric quantification of EndMT-associated marker shown in panel B. [n = 3 independent experiments; *p<0.05 and **p<0.01 compared to control (0)].
Supplementary Figure 2. TLR2 silencing in endothelial cells. HUVECs were transfected with negative control (NC) siRNA or siRNA against TLR2. Total proteins were probed for levels of TLR2. GAPDH was used as loading control. (A) representative immunoblot of TLR2. (B) Densitometric quantification of TLR2 protein levels following siRNA transfection. [n = 3; Data shown as Mean ± SEM; ***p<0.001 compared to control transfection].
Supplementary Figure 3. TLR2 silencing prevents Ang II-induced EndMT protein induction. (A–I) Densitometric quantification of EndMT-associated proteins in HUVECs following TLR2 silencing. HUVECs were transfected with NC siRNA or TLR2 siRNA and then exposed to 10 µM Ang II for 36 h. Data was normalized to GAPDH. Representative western blots are presented in Figure 3A. (J) mRNA levels of Acta2 (α-SMA) in HUVECs exposed to 10 µM Ang II for 24 h following TLR2 siRNA transfection. (K, L) Quantification of CD31 (K) and α-SMA (L) staining of HUVECs. Representative fluorescence images are shown in Figure 3D. [n = 3; Data shown as Mean ± SEM; *p<0.05 and **p<0.01 compared to negative control siRNA transfection; #p<0.05, ##p<0.01, and ###p<0.001 compared to NC siRNA + Ang II].
Supplementary Figure 4. NF-κB inhibition prevents Ang II-induced EndMT in cultured cells. (A–F) Densitometric quantification of EndMT-associated proteins in HUVECs treated with NFκB inhibitor Bay 11-7085 at 5 µM, before exposure to 10 µM Ang II for 36 h. Representative immunoblots are shown in Figure 4A. Data normalized to GAPDH. [n = 3; Data shown as Mean ± SEM; *p<0.05 compared to Control; #p<0.05 and ##p<0.01 compared to Ang II].
Supplementary Figure 5. TLR2 regulates Ang II-induced NF-κB signaling. (A–C) Densitometric quantification of NF-κB signaling proteins in HUVECs transfected with TLR2 siRNA and exposed to 10 μM Ang II for 2 h. Data showing levels of cytosolic p65 subunit of NF-κB (A), nuclear p65 levels (B), and inhibitor of κB in total lysates (C). Data normalized to Lamin B for nuclear proteins and GAPDH for cytosolic proteins. Representative immunoblots are shown in Figure 4B. (D) Proteins levels of TLR2 in HUVECs transfected with TLR2 siRNA and exposed to 10 μM Ang II for 2 h. Data normalized to GAPDH. Representative immunoblots are shown in Figure 4B. (E) Quantitation of EGFP fluorescence intensity in HUVECs transfected with NF-κB reporter. Representative EGFP images are shown in Figure 4E. [n = 3; Data shown as Mean ± SEM; *p<0.05 and **p<0.01 compared to control NC siRNA; #p<0.05, ##p<0.01, and ###p<0.001 compared to NC siRNA+Ang II].
Supplementary Figure 6. TLR2 deficiency does not prevent EndMT induced by paracrine factors generated upon Ang II challenge. (A–G) Densitometric quantification of EndMT-associated proteins in HUVECs exposed to condition media from Ang II-challenged cells. Experimental setup is shown in Figure 5D and representative blots are shown in Figure 5E. Data normalized to GAPDH. [n = 3; Data shown as Mean ± SEM; *p<0.05 and **p<0.01 compared to Control media and NC siRNA; ###p<0.001 compared to NC siRNA; ns = not significant, compared to NC siRNA condition media].
### Supplementary Table 1. Nucleotide sequences for qPCR and gene silencing.

| Gene   | Species | Description                              | Sequence                        |
|--------|---------|------------------------------------------|---------------------------------|
| Col3a1 | Human   | Collagen type III alpha 1 chain          | GGAGCTGGCTACTTCTCGC             |
|        |         |                                          | GGGAAACATCCTCTTCACACAG          |
| Tgfβ1  | Human   | Transforming growth factor β1            | GGGCAGCTCTGCTCAAGC              |
|        |         |                                          | GTGGGTTCACATAGCTGAC             |
| Vim    | Human   | Vimentin                                 | TCCACGCTTTCCCTGTAGG             |
|        |         |                                          | CCCCACCTGTGAGTGTGAGG            |
| Cdh5   | Human   | Vascular endothelial cadherin            | CGAGAGCTACACGTCCTCAAGG          |
|        |         |                                          | GGGTTCGAGGGAAATAGG              |
| Acta2  | Human   | Smooth muscle actin (α-SMA)              | AGAGTTACAGTTGCTGAGT             |
|        |         |                                          | ATGAAGGATGGCTGGAACAG            |
| Tnfa   | Human   | Tumor necrosis factor α                  | CCGTCCCTCTTACTCAGAAGCATCATAGC  |
|        |         |                                          | GGGGATGAGGAGTAGGAAG             |
| Il1β   | Human   | Interleukin 1β                           | ACGCTCGGGGACTCACAGCA            |
|        |         |                                          | TGAGGGCCAAGGCCACAGGTC           |
| Il6    | Human   | Interleukin 6                            | AACCCTGACCTCCAAAGAGGGGGGCAGAGCT|
|        |         |                                          | TCTGCTGTGCTCCCTACTACT           |
| Actb   | Human   | β actin                                  | CCTGCCACCCAGCACCATCAG          |
|        |         |                                          | GCCGATCCACACGGAGTAC             |
| Col3a1 | Mouse   | Collagen type III alpha 1 chain          | CTGTAACATGGAAACTGGGGAAA         |
|        |         |                                          | CCATAGCTGAAGTCAGAAAACCACC      |
| Tgfβ1  | Mouse   | Transforming growth factor β1            | TGACGTCAGTTGAGTGTACGG          |
|        |         |                                          | GTTCATGTCATGAGGTGTGCG           |
| Vim    | Mouse   | Vimentin                                 | CGTCCACACGCACCTACAG            |
|        |         |                                          | GGGGATGAGGAGTAGGAAG             |
| Snai1  | Mouse   | Snail family transcriptional repressor 1 | CACACGCTCCTTGTGTCT              |
|        |         |                                          | GGTGACAAAAACGCGGT              |
| Snai2  | Mouse   | Snail family transcriptional repressor 2 (Slug) | CATCCTTTGGGGGCGTGAAGTC       |
|        |         |                                          | GCCCAGAGACGTGAATAGGTC           |
| Cdh5   | Mouse   | Vascular endothelial cadherin            | CACTGCTTTGGGGGACCTTC           |
|        |         |                                          | GGGGCTCCAAGCCTTCATTTITTCT     |
| Twist1 | Mouse   | Twist family BHLH transcription factor 1 | GGACAAGCTGACGAAATCCTCGGAG     |
|        |         |                                          | CGGAGAAGGCCTGCTGAG             |
| Il1β   | Mouse   | Interleukin 1β                           | ACTCCTTTGACGTTGGGCA            |
|        |         |                                          | CCATCAGAGGCAAGAGGAAGAA         |
| Il6    | Mouse   | Interleukin 6                            | GAGGATACCCACTTCCAAACAGACC      |
|        |         |                                          | AAGTCATCATCTGTTGCTCATACA       |
| Tnfa   | Mouse   | Tumor necrosis factor α                  | CAGGGGGCAACGCTGCTCTC           |
|        |         |                                          | TTTGTGAGTGGTTAGGGGTGCTG        |
| Actb   | Mouse   | β actin                                  | CCGTGGAAAGAGGGCCAGAA           |
|        |         |                                          | TACGACCAGAAGCATACAG           |
| TLR2   | Human   | Toll like receptor 2 (siRNA sequence)    | GCCUCUCUCUAAACUUATT            |
|        |         |                                          | UAAAAGUUUUGAUAGAGGAGGCTT       |
| NC     | Human   | Negative control (siRNA sequence)        | UUCUCUGAAGUGUCAGGUTT          |
|        |         |                                          | ACGUGACACUGUCAGGAATT          |